Merck Sharp & Dohme Corp v. ScieGen Pharmaceuticals, Inc
Merck Sharp & Dohme Corp v. ScieGen Pharmaceuticals, Inc is a federal patent - anda lawsuit filed on 11/15/2021 in the District Court, D. Delaware. The case was terminated on 11/22/2021.
- Court
- District Court, D. Delaware (D. Del.)
Official Court Website → - Assigned judge
- Richard G. Andrews · 4,097 cases in index
- Docket number
- 1:21-cv-01616
- Cause
- 35:271 Patent Infringement
35 U.S.C. § 271 — Patent infringement - Nature of suit
- 835 Patent - Abbreviated New Drug Application(ANDA)
Hatch-Waxman patent disputes over a generic-drug (ANDA) application. - Jurisdiction
- Federal Question
- Jury demand
- None
- Date filed
- 11/15/2021
- Date terminated
- 11/22/2021
1,113 Patent - ANDA cases in this court are indexed here.
Parties
- plaintiff · Merck & Co., Inc Pharmaceuticals & Biotechnology · 24169 cases
- defendant · ScieGen Pharmaceuticals, Inc · 8 cases
Part of a Larger Litigation Pattern
This is one of 9 Patent - ANDA cases in our index naming ScieGen Pharmaceuticals, Inc — a possible mass-tort or coordinated-litigation cluster.
About Patent - ANDA Lawsuits
ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.
Frequently Asked Questions
What is Merck Sharp & Dohme Corp v. ScieGen Pharmaceuticals, Inc?
Merck Sharp & Dohme Corp v. ScieGen Pharmaceuticals, Inc is a federal patent - anda lawsuit filed on 11/15/2021 in the District Court, D. Delaware. The case was terminated on 11/22/2021. ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.
What type of case is this?
It is classified as “Patent - ANDA” under the federal nature-of-suit system. ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.
What court is the case in?
The case is in the District Court, D. Delaware, docket number 1:21-cv-01616.
When was the case filed?
Merck Sharp & Dohme Corp v. ScieGen Pharmaceuticals, Inc was filed on 11/15/2021. It was terminated on 11/22/2021.
What law is the case brought under?
The docket lists the cause as 35 U.S.C. § 271 — Patent infringement.
Other Cases Involving These Parties
Related Patent - ANDA Cases
Source: public U.S. federal court record (docket 61446269).